Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study.

ABSTRACT:

Background

New factors predicting response in patients with a PD-L1 tumor proportion score (TPS) ≥ 50% for locally advanced or metastatic non-small cell lung cancer (NSCLC) are needed to better select first-line therapy. Based on the literature, we previously developed a radiomic model predicting the KEAP1/NFE2L2 mutational status.

Method

This was a retrospective monocenter study including 94 consecutive patients with advanced or metastatic PD-L1 ≥ 50% NSCLC, treated with pembrolizumab, who underwent a pre-therapeutic FDG-PET/CT and were followed up for 1 year. Seventy-seven patients who did not progress within the first 60 days of treatment were analyzed. Each primary lesion was segmented by 2 physicians on PET and CT scans. Radiomic features were calculated using MIM softw

SUBMITTER: Le Meur C 

PROVIDER: S-EPMC12752150 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature